In 2023, Tofersen was approved in the United States for the treatment of adult amyotrophic lateral sclerosis with mutations in the superoxide dismutase 1 (SOD1) gene (Blair, 2023). The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.